VolitionRx Limited
New York Stock Exchange AmericanCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Cameron Reynolds
- Full Time Employees
- 85
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 13215 Bee Cave Parkway Henderson TX United States of America 78738
- IPO Date
- Mar 2, 2012
- CIK
- 0000093314
- Website
- volition.com
- Similar Companies
- Business
- VolitionRx Limited is a multi-national epigenetics company that develops and commercializes simple, easy-to-use, cost-effective blood tests to detect, diagnose and monitor life-altering diseases including cancers and conditions associated with NETosis such as sepsis; key products encompass Nu.Q Vet Cancer Screen, a commercially available screening test for dogs, Nu.Q NETs for immune system monitoring and early sepsis detection, Nu.Q Discover for nucleosome profiling to support drug development, Nu.Q Cancer assays for monitoring disease progression, treatment response and minimal residual disease particularly in non-small cell lung cancer, and Capture-PCR for isolating circulating tumor-derived DNA from plasma samples. Founded in 2010 and headquartered in Henderson, Nevada, the company operates research and development primarily in Belgium with additional facilities and offices in the United States, United Kingdom and Singapore; it employs approximately 80-85 staff and maintains subsidiaries including Volition Germany acquired in 2020. Recent developments include the first commercial sale of Nu.Q Cancer assays in November 2025 to Hospices Civils de Lyon in France for clinical certification ahead of routine use in cancer management, a co-marketing and services agreement with Hologic to promote Nu.Q Discover, inclusion of Nu.Q NETs as an innovative biomarker in France's real-world sepsis evaluation in December 2025, and a $6.0 million underwritten public offering of common stock and warrants completed in October 2025 to fund research, product development and potential acquisitions.
VolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment Monitoring
VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets
VolitionRx Limited (VNRX) Q1 2026 Earnings Call Transcript
VolitionRx Limited Announces First Quarter 2026 Financial Results and Business Update
VolitionRx Limited Schedules First Quarter 2026 Earnings Conference Call and Business Update
VolitionRx Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in Cats
Volition Announces Breakthrough Finger-Prick Detection of Nucleosomes; Expanding Global Market Potential for Sepsis Testing
VolitionRx Announces Acceptance of Compliance Plan by NYSE American
Volition Launches rNuQ™ Webshop Broadening Product Range
VolitionRX Q4 Earnings Call Highlights
VolitionRx Limited (VNRX) Q4 2025 Earnings Call Transcript
VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update
VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in Belgium
Volition Announces Mayo Clinic Study Demonstrates Nu.Q® Concentrations are Elevated in Trauma Patients
Volition Announces Abstract Demonstrating Risk Stratification in Lung Cancer Presented at the European Lung Cancer Conference
VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update
Volition Announces Detection of Over 95% of Early-Stage Cancers
Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating Cancer DNA
Volition Announces First Ever Automated Nu.Q® Vet Cancer Test with Fujifilm Vet Systems
VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution